Jade Biosciences to Participate in Upcoming Conferences
Rhea-AI Summary
Jade Biosciences (Nasdaq: JBIO) will participate in multiple investor conferences in November 2025, including Wedbush Rewind ASN, Stifel Healthcare, TD Cowen Immunology & Inflammation Virtual Summit, and Jefferies Global Healthcare in London.
Scheduled events include a Wedbush fireside chat on Nov 10, 2025 at 12:40 p.m. ET, a Stifel presentation on Nov 12, 2025 at 4:00 p.m. ET, a TD Cowen presentation on Nov 13, 2025 at 3:00 p.m. ET, and a Jefferies presentation on Nov 17, 2025 at 3:30 p.m. GMT. Live webcasts and archived replays will be available on Jade Biosciences' Events & Presentations page for 90 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, JBIO declined 3.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
- Wedbush Rewind ASN Conference 2025 | November 10, 2025
Fireside Chat: Monday, November 10 at 12:40 p.m. ET - Stifel Healthcare Conference | November 11–13, 2025
Presentation: Wednesday, November 12 at 4:00 p.m. ET - TD Cowen Immunology & Inflammation Virtual Summit | November 12-13, 2025
Presentation: Thursday, November 13 at 3:00 p.m. ET - Jefferies Global Healthcare Conference - London | November 18–20, 2025
Presentation: Monday, November 17 at 3:30 p.m. GMT
A live webcast of the presentations will be available on the Events & Presentations page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE-003, an undisclosed antibody discovery program, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Forward-Looking Statements
Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the potential of Jade’s product candidates to become best-in-class therapies and their potential therapeutic uses. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may fail in development, may not receive required regulatory approvals; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contact
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
FAQ
Which conferences will Jade Biosciences (JBIO) attend in November 2025?
When is Jade Biosciences' (JBIO) Wedbush fireside chat in November 2025?
What time is Jade Biosciences' (JBIO) Stifel Healthcare presentation on Nov 12, 2025?
How can investors watch Jade Biosciences (JBIO) presentations from the November 2025 conferences?
When is Jade Biosciences' (JBIO) TD Cowen presentation in November 2025?
What is the date and time of Jade Biosciences' (JBIO) Jefferies Global Healthcare presentation in London?
